TABLE 5.
Summary of the major peptides used for breast cancer therapy.
| Peptides | Sequence/Ref. |
|---|---|
| melittin | GIGAVLKVLTTGLPALISWIKRKRQQ Terwilliger and Eisenberg (1982) |
| iPep697Δ/iPep697/iPep682/iPep624/iPep624W1ΔA/iPep624W2ΔA/iPep624ΔHEX | KKKRKVAPAAVYCTRYSDR/KKKRKVWPAWVYCTRYSDR/KKKRKVPLVWPAWVYCTRYSDRPS/KKKRKVTDSQQPLVWPAWVYCTRYSDRPS/KKKRKVTDSQQPLVAPAWVYCTRYSDRPS/KKKRKVTDSQQPLVWPAAVYCTRYSDRPS/KKKRKVTDSQQPLVGAAGAGCTRYSDRPS Beltran et al. (2014) |
| EN1-iPep/Mutant EN1-iPep | KKKRVPLVWPAWVYCTRYSDR/KKKRKVPLVWPAWVYCTRYSDR/KKKRVPLVAPAAVYCTRYSDR/KKKRKVPLVAPAAVYCTRYSDR Sorolla et al. (2019) |
| [R5K]W7A | [R5K]W7A Mozaffari et al. (2021) |
| Nap-GFFpYK | Nap-GFFpYK Zhang et al. (2020) |
| P1/P2/P3/P4/P5/P6/P7 | NmFARKGALRQ/FARKGALRQ/NmRFARKGALRQKNV/RFARKGALRQKNV/NmRKRTLRRL/RKRTLRRL/NmNDSRSSLIRKR Gupta et al. (1996) |
| tetrapeptide | GFLG (Zhi et al., 2019) |
| T10-ERK | HAIYPRHGGCGMPKKKPTPIQLNP Sheng et al. (2016) |
| GFLG | GFLG Wang et al. (2020) |
| caPeptide | CLGIPEQEY Lingeman et al. (2014) |
| RAN-IP | CAQPEGQVQFK Haggag et al. (2019) |
| NT4 | (ELYENKPRRPYIL)4 Brunetti et al. (2016) |
| [F7,P34]-NPY | YPSKPDFPGEDAPAEDLARYYSALRHYINLITRPRY Böhme et al. (2016) |
| ERAP | 11R-GGG-QMLSDLTLQLRQR Yoshimaru et al. (2013) |
| IF7 | IFLLWQR Yu et al. (2015) |
| ASRPS | MTTKMRRLRPSAPSGLGQEQEAEVVEGCFPAVTETPFAPAYIKKRGGRIWSSDPRSDGEH Wang et al. (2020) |
| AFPeq | cyclo(EKTOVNOGN) Jacobson et al. (2014) |
| Pasireotide | cyclo(Hyp(Unk)-Phg-WKY(Bn)F) Herbert (2008) |
| goserelin | XHWSYSLRP Parker and Schimmer (2001) |